Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
January 10, 2024 at 07:20 am EST
Share
Rapid Micro Biosystems, Inc. provided revenue guidance for the fourth quarter and full year 2023. for the quarter, the company expects total revenue expected to be between $6.2 million and $6.4 million, representing growth of approximately 45% compared to the prior-year period .
For the full year, the company expects total revenue expected to be between $22.4 million and $22.6 million, representing growth of over 30% compared to the prior year.
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
RAPID MICRO BIOSYSTEMS, INC. 
